I KNEW WITH
TAVR by Edwards
I WAS IN GOOD
HANDS

RICK|REAL TAVR PATIENT AND CARDIAC SURGEON

Watch his story

Looking for a TAVR Hospital near you?

This helpful tool can show you the closest Heart Valve Team based on your location.

Find one here

YOUR VALVE CHOICE MATTERS

Not all TAVR (transcatheter aortic valve replacement) valves are the same

The SAPIEN 3 Ultra RESILIA valve is the latest valve approved in the SAPIEN 3 TAVR family of valves.

The SAPIEN 3 Ultra RESILIA valve is the latest valve approved in the SAPIEN 3 TAVR family of valves

TAVR by Edwards is the #1 choice in the U.S. for heart valve replacement. And over 1 million people worldwide have received TAVR by Edwards.

The SAPIEN 3 Ultra RESILIA valve is made of cow heart tissue that uses advanced technology to block the buildup of calcium. This RESILIA tissue treatment could potentially allow the valve to last longer.*†1

TAVR by Edwards is the first and only TAVR approved for all heart valve failure patients.‡

*RESILIA tissue has not been studied for long-term results in patients.

†RESILIA tissue tested against tissue from commercially available bovine pericardial valves from Edwards Lifesciences in a juvenile sheep model.1

‡Edwards TAVR has been approved for all severe aortic stenosis patients whether they have symptoms or not.

WHY CHOOSE TAVR?
SEE THE BENEFITS FOR YOURSELF

Most patients:

Icon of a person inside a house
  • Have a short recovery time and go home the next day
  • Are up and walking in a few hours
  • Are back to feeling like themselves in as little as 30 days
  • Are done with the procedure in about an hour
Icon of 98 percent

Over 98% of TAVR recipients did not require a valve reintervention after 10 years of receiving their valve§2

§Based on Medicare claims data which may underestimate the actual event rate.2

ASK FOR THE
EDWARDS SAPIEN 3 ULTRA RESILIA VALVE

The type of TAVR valve you receive can impact your heart and your future

Icon of a heart beat

Designed like your heart valve

  • The TAVR valve is designed to work just like the one inside your body and begins to work immediately once implanted
Icon of a checkmark

Designed to last

  • The frame of the valves is made from specialized materials for strength and durability
  • Edwards TAVR has better outcomes than open heart surgery in low-risk patients at 1 year—and has proven equally effective at 5 years¶3,4
Icon of person with stars next to their head

Designed in different sizes to fit your anatomy

  • Edwards TAVR valves are not one size fits all. They come in 4 sizes to meet the individual needs of each patient
  • Edwards TAVR could be considered the preferred treatment option for women, based on the first and only 100% female study5,6
Icon of two hands holding up a heart

Designed for your future

  • If you’re like many patients with coronary artery disease, an Edwards TAVR valve means your physicians may have better access to your coronary arteries, should you ever need another procedure

As with any medical procedure, there is a possibility of risks. The most serious risks of TAVR include death, stroke, serious damage to the arteries, or serious bleeding. Talk to a Heart Team about whether TAVR is right for you.

The PARTNER 3 Trial, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint of all-cause death, all stroke, and re-hospitalization (valve-related or procedure-related and including heart failure) at one year, and multiple pre-specified secondary endpoints in low risk patients.

PARTNER 3 Trial 5-Year Results in low-risk patients – Low rates of cardiovascular mortality through five years (5.5% SAPIEN 3 TAVR to 5.1% SAVR). Low rates of all-cause mortality through five years (10.1% SAPIEN 3 TAVR vs. 8.2% with SAVR). Low rates of disabling stroke through five years (2.9% SAPIEN 3 TAVR to 2.7% SAVR). Low rates of stroke through five years (5.8% SAPIEN 3 TAVR vs. 6.4% SAVR). Lower rates of rehospitalization with SAPIEN 3 TAVR through five years (13.7% vs. 17.4%).

Find a TAVR Hospital near you

Is TAVR right for you? A Heart Valve Team can help determine your treatment options.

Find one here
Icon of a hospital

Get your TAVR Info Kit

Each kit is packed with valuable information and resources to help you better understand TAVR.

Get your kit
Info kit icon
References: 1.Flameng W, Hermans H, Verbeken E, Meuris B. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015;149(1):340-345. 2.Baron SJ, Ryan MP, Chikermane SG, Thompson C, Clancy S, Gunnarsson CL. Long-term risk of reintervention after transcatheter aortic valve replacement. Am Heart J. 2024;267:44-51. 3.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med. 2023;389(21):1949-1960. 4.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705. 5.Eltchaninoff H, Bonaros N, Prendergast B, et al. Rationale and design of a prospective, randomized, controlled, multicenter study to evaluate the safety and efficacy of transcatheter heart valve replacement in female patients with severe symptomatic aortic stenosis requiring aortic valve intervention (Randomized researcH in womEn all comers wIth Aortic stenosis [RHEIA] trial). Am Heart J. 2020;228:27-35. 6.Eltchaninoff H, Tchétché D. Transcatheter versus surgical aortic valve replacement in women (Randomized researcH in womEn all comers wIth Aortic stenosis [RHEIA] trial). Presented at: ESC Congress 2024. August 31, 2024.

Patients and/or clinicians quoted on this website have received compensation from Edwards Lifesciences.